ReviewFrontiers in pharmacology2022
The effects of bioactive components from the rhizome of
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Herbal Interventions in Parkinson's Disease: A Systematic Review of Preclinical Studies.Cellular and molecular neurobiology · 2025Pooled it
- Comparative Evaluation of Phenolic Composition and Antioxidant Activities ofFoods (Basel, Switzerland) · 2026Article
- P-Hydroxybenzaldehyde fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Zhigancao decoction alleviates Parkinson's disease via inhibiting TNF/NF-κB and Ras/ERK-mediated neuroinflammation and apoptosis.iScience · 2026Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- GePIF4 Increases the Multi-Flower/Capsule-Bearing Traits and Gastrodin Biosynthesis inPlants (Basel, Switzerland) · 2025Article
- Xifeng Jiannao pill mitigates MPTP-induced neuronal apoptosis by reducing inflammation and oxidative stress via MAPK signaling.Metabolic brain disease · 2025Article
- Genome-wide identification of carboxyesterase family members reveals the function of GeCXE9 in the catabolism of parishin A in Gastrodia elata.Plant cell reports · 2025Article
- Neuropharmacological effects ofFrontiers in neurology · 2025Review
- From molecules to medicine: a systematic review of Gastrodia elata's bioactive metabolites and therapeutic potential.Frontiers in pharmacology · 2025Review
- Effects of Nutraceutical Compositions Containing Rhizoma Gastrodiae or Lipoic Acid in an In Vitro Induced Neuropathic Pain Model.International journal of molecular sciences · 2024Article
- The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach.International journal of molecular sciences · 2024Review
- Research overview on the genetic mechanism underlying the biosynthesis of polysaccharide in tuber plants.PeerJ · 2024Review
- Identifying the quality markers and optimizing the processing of Gastrodiae rhizoma to treat brain diseases.Frontiers in pharmacology · 2024Article
- Bioactivity Profiling and Quantification of Gastrodin inInternational journal of molecular sciences · 2023Article
- Article
- GelFAP v2.0: an improved platform for Gene functional analysis in Gastrodia elata.BMC genomics · 2023Article
- TCM "medicine and food homology" in the management of post-COVID disorders.Frontiers in immunology · 2023Review
- FreshFrontiers in pharmacology · 2023Article
- The role of symbiotic fungi in the life cycle ofFrontiers in plant science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is an age-related chronic neurodegenerative disease caused by the death and degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The decrease of the neurotransmitter dopamine in the patient's brain leads to various motor symptoms. PD drugs mainly enhance dopamine levels but cannot prevent or slow down the loss of dopaminergic neurons. In addition, they exhibit significant side effects and addiction issues during long-term use. Therefore, it is particularly urgent to develop novel drugs that have fewer side effects, can improve PD symptoms, and prevent the death of dopaminergic neurons. The rhizome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.